BOSTON and MONTREAL, Nov. 29, 2023 /CNW/ – enGene Holdings Inc. (“enGene,”) (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) $138M in
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
BOSTON and MONTREAL, Sept. 7, 2023 – enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other
enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Interim Phase 1 results from enGene’s Phase 1/2 LEGEND study of intravesical EG-70 (detalimogene voraplasmid) demonstrate a 71% CR rate at three months in patients with high-grade non-muscle invasive bladder
enGene Appoints Alex Nichols, PhD as President and Chief Operating Officer
BOSTON, MA and MONTREAL, Feb. 2, 2023 – enGene, Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX
enGene Appoints James C. Sullivan, PhD as Chief Scientific Officer
BOSTON and MONTRÉAL, March 17, 2022 – enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform,
enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
83% of patients evaluable for efficacy achieved Complete Response (CR) at 3-months No Dose-Limiting Toxicities or Serious Adverse Events have been reported in the study Adverse Events (AEs) were limited
enGene Announces Poster Presentation at the Society of Urologic Oncology 2021 Annual Meeting
– Preclinical EG-70 studies reveal durable systemic anti-tumor immunity and robust efficacy in an orthotopic murine model of bladder cancer – EG-70 is a first-in-class non-viral genetic medicine encoding RIG-I
enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial
– EG-70 is a first-in-class intravesical non-viral genetic medicine encoding RIG-I activators and IL-12 as a monotherapy – First clinical candidate from company’s novel proprietary platform engineered to activate both
enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer
BOSTON and MONTRÉAL, Dec. 3, 2020 – enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today
